The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Open accessAbstract
The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years. We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (minimum inhibitory concentration 0.06 mug/ml). In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit. Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations. A single dose of R207910 inhibited mycobacterial growth for 1 week. Plasma levels associated with efficacy in mice were well tolerated in healthy human volunteers. Mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 14 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 was extensively distributed to tissues, including lungs and spleen (Fig. 3A, table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These average concentrations were greater than that achieving optimal activity in established infection in mice.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Low MICs were also found for other mycobacterial species, including Mycobacterium bovis, Mycobacterium kansasii and Mycobacterium ulcerans, as well as species naturally resistant to many other anti-TB agents and involved in opportunistic infections, such as Mycobacterium avium complex (MAC), Mycobacterium abscessus, Mycobacterium fortuitum and Mycobacterium marinum (Table 1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 25 mg/kg, the activity of R207910 was significantly better than at 12.5 mg/kg (P = 0.005).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The bactericidal activity obtained by the RHZ combination after 2 months of therapy was matched by the combinations JHZ and RJZ after just 1 month of therapy.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, at 12.5 and 25 mg/kg, R207910 was significantly more active (P = 0.005) than 25 mg/kg isoniazid, a drug known for its strong, early bactericidal activity (Fig. 4A).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, the susceptibility of R207910-resistant M. tuberculosis strains remained unchanged to other anti-TB agents, including isoniazid, rifampin, streptomycin, amikacin, ethambutol and moxifloxacin.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“To date, 20 molecules of the DARQ series have a minimum inhibitory concentration (MIC) below 0.5 µg/ml against M. tuberculosis H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data from a multiple-ascending-dose study have shown an increase (approximately by a factor of two) in AUC 0-24h from Day 1 to Day 14 of once-daily dosing at 50, 150 and 400 mg R207910, without substantial variation between subjects.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Plasma levels associated with efficacy in mice are well tolerated in healthy human volunteers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclear
- Probably not a substantial claim. 3
- It may state two separate claims as one. 40
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The most active compound of the class, R207910, is a pure enantiomer with two chiral centers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“No accumulation of R207910 was observed after five daily oral doses, indicating that slow redistribution from tissues contributed to the relatively long half-lives in plasma.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the second study, the good tolerability was maintained; only one subject withdrew from the study, because of a urinary tract infection (unrelated to R207910) after seven doses at 150 mg/day.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When added to the first-line triple TB therapy combination RHZ, 25 mg/kg R207910 (J) increased the drop in bacterial load in the lungs by 2 log 10 after 1 month of therapy compared with standard RHZ treatment regimen, and a further 1 log 10 drop after 2 months.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maximum plasma concentrations (C max ) of 0.40-0.54µg/ml with a single 6.25 mg/kg/dose were achieved within 1 hour and 1.1-1.3µg/ml with a 25 mg/kg/dose within 2-4 hours.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The majority of adverse events reported (supporting online text), were considered possibly related to the study medication-placebo (seven of 18 subjects) or R207910 (20 of 36 subjects).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The AUC showed a better correlation with the dose than C max , reflecting limitations in rate of absorption at higher dosing regimens, as confirmed in a single-dose pharmacokinetic study comparing C max and AUC after 6.25, 25 and 100 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This anti-mycobacterial-specific spectrum differs from that of isoniazid, which has very poor activity against MAC.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In studies using oral treatment of R207910 for 5 days per week for 4 weeks, starting the day after inoculation, the minimal dose of R207910 that prevented mortality in nonestablished infection was 1.5 mg/kg, and the minimal effective dose (MED) preventing gross lung lesions was 6.5 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposure of M. tuberculosis in log-phase growth to concentrations of R207910 at 10-fold MIC resulted in a 3 log 10 reduction in bacterial counts after 12 days, indicating that R207910 has bactericidal activity in vitro (table S2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Complementation studies have verified that the mutant atpE gene is responsible for resistance to R207910, implying that the atpE gene product is the target of R207910 in mycobacteria.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The range of MICs for the international reference strain M. tuberculosis H37Rv and six fully antibiotic susceptible isolates was 0.03-0.120µg/ml (Table 1), versus 0.500 µg/ml for rifampin and 0.120 µg/ml for isoniazid (results not shown).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 30 isolates of MDR-TB tested were susceptible to 0.100 µg/ml of R207910, and 17 (57%) were susceptible to 0.010 µg/ml of R207910 (Table 2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pharmacokinetic results from the single-ascending-dose study suggested that R207910 is well absorbed after single oral administration, and the peak concentration was reached at 5 hours (median value) post-dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 had much higher MICs for Corynebacterium and Helicobacter pylori (MIC 4.0 µg/ml), and especially for other organisms such as Gram-positive Nocardia, Streptococcus pneumoniae, Staphylococcus aureus and Enterococcus faecalis, or Gram-negative Escherichia coli and Haemophilus influenzae (table S1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Half-lives ranged from 43.7 to 64 hours in plasma and 28.1 to 92 hours in tissues (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of drugs included in the World Health Organization's firstline tuberculosis treatment regimen (rifampin, isoniazid and pyrazinamide) with R207910 accelerates bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The DARQ R207910 is a member of a new chemical class of anti-mycobacterial agents and has an MIC equal to or lower than that of reference compounds.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A single dose of 50 mg/kg R207910 in the non-established infection murine model of TB infection resulted in a bacteriostatic effect (0.5 log 10 drop in bacterial count in the lungs), which lasted for 8 days-a similar effect to that of rifapentine (10 mg/kg) (Fig. 3B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In established infection (treatment beginning 12-14 days after inoculation when bacterial load was 5.94 log 10 CFU), 25 mg/kg R207910 as monotherapy was at least as active as the triple combination therapy (rifampin [R] + isoniazid [H] + pyrazinamide [Z]), and more active than rifampin alone (Fig. 4B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (MIC 0.06 µg/ml).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean AUC 0-24h values were 7.91, 24 and 52 µg/hour/ml at steady state, corresponding to average concentrations of 0.33, 1.0 and 2.2 µg/ml across a dosing interval, with 50, 150 and 400 mg/day, respectively.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pharmacokinetics of R207910 were linear up to the highest dose tested (700 mg); both C max and AUC increased proportionally with the administered dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The two point mutations identified (D32V for M. smegmatis and A63P for M. tuberculosis) are both in the membrane-spanning domain region of the protein.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Areas under the concentration-time curve (AUCs) ranged from 5.0 to 5.9 µg/hour/ml with a 6.25 mg/kg/dose and 18.5 to 19.4 µg/hour/ml with a 25 mg/kg/dose (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“From selection experiments, the proportion of resistant mutants that emerged was 5 x 10 -7 and 2 x 10 -8 at four-fold MIC, and 5 x 10 -8 and 1 x 10 -8 at eight-fold MIC for M. tuberculosis and M. smegmatis, respectively (8).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [8] 8. Details of materials and methods and supporting online text are available as supporting material on Science Online.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of each of the three first-line drugs with R207910 resulted in a dramatic increase in potency, leading to complete culture conversion of the lungs in some animals after only 2 months of treatment.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 has potent early bactericidal activity in the nonestablished murine TB model, matching or exceeding that of isoniazid (Fig. 4A), which is consistent with in vitro observations pointing to a bactericidal activity.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, the bactericidal potency seen upon administration of a single dose of 100 mg/kg R207910 in vivo was similar to the effect seen upon continuous exposure of cultures to 0.6 µg/ml (or 10-fold the median MIC of the H37Rv strain) in vitro, giving a first indication of the pharmacodynamics of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the minimal bactericidal dose was very close to the MED, a finding confirming timedependent, rather than concentration-dependent, activity of R207910 in vitro.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data suggest that maintaining average plasma levels of 0.3 µg/ml/day across a dosing interval, which is achieved with a 100 mg/kg/week dose, is necessary to achieve optimal effect of monotherapy in mice infected with strain H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The killing effect was not increased by higher concentrations of the compound, suggesting the killing was time-dependent rather than concentration-dependent.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although current first-line anti-TB drug regimens can achieve more than 99% efficacy, this is often reduced because of drug resistance (5).”
What the sources say
- Not matchedcites [5] 5. R. J. O'Brien, P. P. Nunn, Am. J. Respir. Crit. Care Med. 163, 1055 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Not matched
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Structurally and mechanistically, DARQs are very different from both fluoroquinolones (including methoxyquinolones) and other quinoline classes, including mefloquine and its analogs 4-methylquinolines and 4quinolylhydrazones (9-13).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [9] 9. R. Jain, B. Vaitilingam, A. Nayyar, P. B. Palde, Bioorg. Med. Chem. Lett. 13, 1051 (2003).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [10] 10. C. M. Kunin, W. Y. Ellis, Antimicrob. Agents Chemother. 44, 848 (2000).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [11] 11. M. R. Barbachyn, S. J. Brickner, Patent (International Publication Number: WO 93/09103, International Publication Date: 13 May, 1993, International Application Number: PCT/US92/08267, International Filing Date: 1992).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [12] 12. L. Savini, L. Chiasserini, A. Gaeta, C. Pellerano, Bioorg. Med. Chem. 10, 2193 (2002). / www.sciencexpress.org /9 December 2004 / Page 4/ 10.1126/science.1106753
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [13] 13. S. Vangapandu, M. Jain, R. Jain, S. Kaur, P. P. Singh, Bioorg. Med. Chem. 12, 2501 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The long half-lives and consequently prolonged exposure are important factors determining the duration of activity in vivo and provide a rationale for less frequent dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A comparison of the sequences of ATP synthases of different bacteria and of eukaryotic ATP synthase provides a rationale for the specificity of the antibacterial spectrum and, to a lesser extent, the safety profile of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, the distinct target of R207910 means that there is no crossresistance with existing anti-TB drugs, and our studies verified it is as effective against MDR strains as it is against fully antibiotic-susceptible strains.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Inhibition of ATP synthase function may lead to ATP depletion and imbalance in pH homeostasis, both contributing to decreased survival (15,16).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [15] 15. M. Rao, T. L. Streur, F. E. Aldwell, G. M. Cook, Microbiology 147, 1017 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [16] 16. G. Deckers-Hebestreit, K. Altendorf, Annu. Rev. Microbiol. 50, 791 (1996).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These are all attributes that are valuable for treatment of chronic infections and they may also be important for the development of simpler dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [17] 17. E. L. Nuermberger et al., Am. J. Respir. Crit. Care Med. 169, 421 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
The paper relies on this without support.
No tuberculosis-specific drugs have been discovered in 40 years.
“Tuberculosis has been increasing significantly on a worldwide basis over the past decade, but no tuberculosisspecific drugs have been discovered in 40 years.”
The paper relies on this without support.
The murine TB model is predictive of human TB treatment outcomes.
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TMC207 is bactericidal towards most species of mycobacteria (109), but is only bacteriostatic against M. avium (118) and M. smegmatis (Berney and Cook, unpublished data).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When mycobacterial cells (growing or non-growing) are treated with TMC207, time-dependent (not dose-dependent) killing is observed (109).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“M. smegmatis was used for the initial compound screening that identified diarylquinoline (later named Bedaquiline) as a specific inhibitor of mycobacterial ATP synthase in 2005, which ended a 40-year dearth in anti-TB drug discovery (147).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Bedaquiline, the first new TB drug in 40 years, was discovered through an M. smegmatis screen.”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Citations
Cites
Amino acid substitution matrices from protein blocks.
Henikoff, S., & Henikoff, J. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10915 · Cited by 6,218
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Comparing the Means of Several Groups
Godfrey, K. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132305 · Cited by 740
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Nuermberger, E. L., Yoshimatsu, T., Tyagi, S. K., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200310-1380oc · Cited by 315
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis
Siddiqi, S. H., Libonati, J. P., & Middlebrook, G. (1981) · Journal of Clinical Microbiology · doi:10.1128/jcm.13.5.908-912.1981 · Cited by 242
The Need for New Drugs against Tuberculosis
O'BRIEN, R. J., & NUNN, P. P. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2007122 · Cited by 221
THE F0F1-TYPE ATP SYNTHASES OF BACTERIA: Structure and Function of the F0 Complex
Deckers-Hebestreit, G., & Altendorf, K. (1996) · Annual Review of Microbiology · doi:10.1146/annurev.micro.50.1.791 · Cited by 195
Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG
Rao, M., Streur, T. L., Aldwell, F. E., & Cook, G. M. (2001) · Microbiology · doi:10.1099/00221287-147-4-1017 · Cited by 148
Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones
Savini, L., Chiasserini, L., Gaeta, A., & Pellerano, C. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00071-8 · Cited by 134
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,301–1,400 of 2,159
Machura, B., Wolff, M. J., Cieślik, W., et al. (2013) · Polyhedron · doi:10.1016/j.poly.2012.12.028 · Cited by 12
What′s in a Name? Can Mullein Weed Beat TB Where Modern Drugs Are Failing?
McCarthy, E., & O’Mahony, J. (2010) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2011/239237 · Cited by 12
“The three compounds which are currently in phase II/III clinical development (namely moxifloxacin, PA824, and TMC207) elicit their activity by the inhibition of enzymes involved in cell division, respiration, and mycolic acid synthesis [13, 14].”
BackgroundLerner, C. G., Kakavas, S. J., Wagner, C., Chang, R. T., Merta, P. J., Ruan, X., Metzger, R. E., & Beutel, B. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2767-2777.2005 · Cited by 13
“Target identification methods have also been described which make use of classical genetic mapping (13), cloning (2, 17, 52), error-prone PCR (7), antisense technology (55), and genome sequence analysis (3).”
BackgroundMethodMechanism of Drug Resistance in Mycobacterium tuberculosis
Pym, A. S., & Cole, S. T. (2007) · CRC Press eBooks · doi:10.1201/9781420008753.ch13 · Cited by 12
Yücesoy, B. (2005) · Thorax · doi:10.1136/thx.2004.029090 · Cited by 12
Toward a New Therapy for Tuberculosis
Rubin, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmcibr044438 · Cited by 12
Perveen, S., Pal, S., & Sharma, R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00829d · Cited by 13
Structure and assembly of the MmpL5/MmpS5 efflux transporter from Mycobacterium tuberculosis
Xiong, Z., Yang, X., Wang, S., Smart, C. J., Sisson, H. M., Lin, Z., Hu, T., Ran, Y., Xu, C., Yang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60365-5 · Cited by 13
Berida, T. I., McKee, S. R., Chatterjee, S., Manning, D. L., Li, W., Pandey, P., Tripathi, S., Mreyoud, Y., Smirnov, A., Doerksen, R. J., et al. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00341 · Cited by 13
Targeting Mycobacterium tuberculosis pH-driven adaptation
Dechow, S. J., & Abramovitch, R. B. (2024) · Microbiology · doi:10.1099/mic.0.001458 · Cited by 14
“In recent years, numerous compounds have been identified that disrupt Mtb pH IB : bedaquiline [86], IDR-0020850, IDR-0054790, IDR-0099118, IDR-0040669, IDR-0081053 [72], nitazoxanide [87], monensin [71], 1048, 20E11, 1G9, 23A6 [71], BO43 [80] and imidazopyradines [88, 89].”
BackgroundSingh, M., Dhanwal, A., Verma, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63051-6 · Cited by 11
Mycobacterium tuberculosis F-ATP Synthase Inhibitors and Targets
Harikishore, A., & Grüber, G. (2024) · Antibiotics · doi:10.3390/antibiotics13121169 · Cited by 11
Antibacterial Drug Discovery: Doing It Right
Gengenbacher, M., & Dick, T. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.005 · Cited by 11
“Those do work, as once again demonstrated by the new tuberculosis drug, bedaquiline (Andries et al., 2005).”
BackgroundFiołka, M. J., Grzywnowicz, K., Mendyk, E., et al. (2015) · Apmis · doi:10.1111/apm.12466 · Cited by 11
Palladium-catalyzed dimerization of N -aryl propargylamines for the synthesis of 3-vinylquinolines
Li, X., Zhang, X., Hu, B., et al. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob00133b · Cited by 11
Bedaquiline in Drug-Resistant Tuberculosis: A Mini-Review
Singh, B. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220421130707 · Cited by 11
Kalsum, S., Otrocka, M., Andersson, B., Welin, A., Schön, T., Jenmalm-Jensen, A., Lundbäck, T., & Lerm, M. (2022) · Tuberculosis · doi:10.1016/j.tube.2022.102222 · Cited by 11
Synthesis and Evaluation of Pseudomonas aeruginosa ATP Synthase Inhibitors
Ciprich, J. F., Buckhalt, A. J. E., Carroll, L. L., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c03127 · Cited by 11
Можокина, Г. Н., Samoylova, А. G., Vasilyeva, I. A., & Russkikh, A. (2022) · Tuberculosis and lung diseases · doi:10.21292/2075-1230-2022-100-8-54-64 · Cited by 12
Chauhan, P., Datta, I., Dhiman, A., Shankar, U., Kumar, A., Vashist, A., Sharma, T. K., & Tyagi, J. S. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00414 · Cited by 11
Yao, G., Zhu, M., Nie, Q., Chen, N., Tu, S., Zhou, Y., Xiao, F., Liu, Y., Li, X., & Chen, H. (2023) · Journal of International Medical Research · doi:10.1177/03000605221148416 · Cited by 14
“Bedaquiline is a diarylquinoline that disrupts the activity of the mycobacterial adenosine triphosphate (ATP) synthase.(12) The drug binds to the oligomer subunit C of ATP synthetase(13) and affects the activity of the ATP synthetase proton pump leading to obstruction of ATP synthesis.”
BackgroundSelf-citationMind the gap. Rolling out new drug resistant tuberculosis regimens with limited diagnostic tools
Saluzzo, F., & Cirillo, D. M. (2023) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2023.100350 · Cited by 11
“In South Africa and Taiwan Bedaquiline resistance in MDR/RR-TB population is currently reported around 3 % in patients with previous exposure to Bedaquiline or Clofazimine and solely associated to Rv0678 mutations in the South African study [12].”
MethodInfluentialGaglani, P., Dwivedi, M., Upadhyay, T. K., Kaushal, R. S., Ahmad, I., & Saeed, M. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1152269 · Cited by 12
Drug Targets, Target Identification, Validation, and Screening
den Broeck, W. M. M. V. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00003-1 · Cited by 11
Identification of the anti‐mycobacterial functional properties of piperidinol derivatives
Guy, C. S., Tichauer, E., Kay, G. L., Phillips, D. J., Bailey, T. L., Harrison, J., Furze, C. M., Millard, A. D., Gibson, M. I., Pallen, M. J., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13744 · Cited by 10
“…used in high-throughput screening campaigns to identify new TB drugs, including the clinically approved anti-tubercular agent bedaquiline (Andries et al., 2005), we chose to use this organism to generate spontaneous resistant mutants due to the ease and speed of manipulation despite the…”
InfluentialSmall Molecule and Peptide Recognition of Protein Transmembrane Domains
Zeng, X., Wu, P., Yao, C., Liang, J., Zhang, S., & Yin, H. H. (2017) · Biochemistry · doi:10.1021/acs.biochem.6b00909 · Cited by 11
Muscia, G. C., Carnevale, J. P., Luczywo, A., Peláez, M. V., Toole, A. R. Ó., Buldain, G., Casal, J. J., & Ası́s, S. E. (2018) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2018.10.003 · Cited by 11
Interaction of the anti-tuberculous drug bedaquiline with artificial membranes and rat erythrocytes
Belosludtsev, K. N., Penkov, N. V., Tenkov, K. S., Talanov, E. Y., Belosludtseva, N. V., Agafonov, A. V., Stepanova, A. E., Starinets, V. S., Ващенко, О. В., Gudkov, S. V., et al. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.11.017 · Cited by 11
Targeting drugs for tuberculosis
Smith, T. C., & Aldridge, B. B. (2019) · Science · doi:10.1126/science.aay0211 · Cited by 11
Kumar, A., Karkara, B. B., & Panda, G. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13934 · Cited by 12
Targeting the cytochrome bc1 complex for drug development in M. tuberculosis: review
Wani, M. A., & Dhaked, D. K. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10335-y · Cited by 11
“Bedaquiline belongs to the diarylquinoline class of drugs and is the only medication approved for tuberculosis in the last 40 years [26].”
BackgroundBuravchenko, G. I., Maslov, D. A., Alam, M. S., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15020155 · Cited by 11
Harbut, M. B., Yang, B., Liu, R., Yano, T., Vilchèze, C., Cheng, B., Lockner, J. W., Guo, H., Yu, C., Franzblau, S. G., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201800260 · Cited by 11
New anti-tuberculosis therapies
Portero, J. L., & Rubio, M. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.6.617 · Cited by 11
“3 μg/ml through a daily dose, although these levels are also achievable with a dose of 100 mg/kg per week [43] .”
BackgroundInfluentialRETRACTED: Cytotoxicity and Anti-Inflammatory Activity of Methylsulfanyl-Triazoloquinazolines
Al‐Salahi, R. A., Gamal‐Eldeen, A. M., Alanazi, A. M., et al. (2013) · Molecules · doi:10.3390/molecules18021434 · Cited by 11
“In addition, the quinazoline moiety is present in many classes of biologically active compounds, a number of which have been used clinically as antifungal, antibacterial and antiprotozoic drugs [15,16], antituberculotic agents [17–19].”
RetractedTomioka, H. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.1.21 · Cited by 12
“However, at present, only a few drugs, such as nitroimidazopyran PA-824, nitroimidazooxazole OPC-67683, diarylquinoline TMC-207, pyrrole LL-3858 and linezolid, are in clinical trials.”
BackgroundInfluentialChander, S., Ashok, P., Cappoen, D., et al. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12788 · Cited by 11
Wang, L., Xu, M., Southall, N. T., Zheng, W., & Wang, S. (2016) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207319666161010163249 · Cited by 12
“Assay principle Because PhoP-DNA binding is essential for the PhoP function as a transcriptional regulator in regulating MTB virulence, disrupting the PhoP-DNA interaction should attenuate the MTB virulence.”
BackgroundInfluentialNew drugs and vaccines for drug-resistantMycobacterium tuberculosisinfections
Dover, L. G., Bhatt, A., Bhowruth, V., Willcox, B. E., & Besra, G. S. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.4.481 · Cited by 11
Pédelacq, J. D., Nguyen, M. C., Terwilliger, T. C., & Mourey, L. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch23 · Cited by 12
Application of antimicrobial drugs in Mycobacterium tuberculosis and research progress
Wang, Y., Cao, D., & Liu, G. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107794 · Cited by 13
Umbrasas, D., Arandarčikaitė, O., Grigalevičiūtė, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189717 · Cited by 10
“Initially, BDQ was reported to be selective for mycobacterial ATPase with minimal or no inhibitory effect on mammalian enzyme [37,38].”
BackgroundMehta, K., Guo, T., van der Graaf, P. H., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15925 · Cited by 10
Aina, O. S., Rofiu, M. O., Oloba‐Whenu, O. A., et al. (2023) · Scientific African · doi:10.1016/j.sciaf.2023.e01985 · Cited by 10
Kumari, N., Sharma, R., Ali, J., Chandra, G., Singh, S., & Krishnan, M. Y. (2024) · Tuberculosis · doi:10.1016/j.tube.2024.102479 · Cited by 12
Harrison, G. A., Wang, E. R., Cho, K., Mreyoud, Y., Sarkar, S., Almqvist, F., Patti, G. J., & Stallings, C. L. (2024) · mBio · doi:10.1128/mbio.02968-23 · Cited by 14
“To determine if the GHTB136 and GHTB146 strains are more generally resistant to ATP depletion, we quantified the sensitivity of the C10-resistant mutants to the ATP synthase inhibitor bedaquiline (BDQ) or the protonophore CCCP, compounds known to inhibit ATP synthesis by targeting the electron transport chain (ETC) (2…”
MethodCui, Y., Lanne, A., Peng, X., Browne, E., Bhatt, A., Coltman, N. J., Craven, P. G. E., Cox, L. R., Cundy, N. J., Dale, K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01643 · Cited by 11
Umpeleva, T. V., Chetverikova, E., Belyaev, D. V., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03749-23 · Cited by 10
Saranathan, R., Rourke, A. K., Asare, E., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae438 · Cited by 10
Ibrahim, M. A. A., Mahmoud, D. G. M., Abdelrahman, A. H. M., Abdeljawaad, K. A. A., Mekhemer, G. A. H., Shoeib, T., El‐Tayeb, M. A., Sidhom, P. A., Paré, P. W., & Hegazy, M. F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314422 · Cited by 10
Vilchèze, C., Saranathan, R., Kalluru, R. S., Banaei, N., & Jacobs, W. R. (2025) · mBio · doi:10.1128/mbio.01484-25 · Cited by 11
New drugs for tuberculosis treatment
Sánchez, F., López-Colomés, J. L., Villarino, E., & Grosset, J. H. E. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70018-0 · Cited by 10
Potential Natural Antimycobacterial Metabolites from Some Sub-Saharan Medicinal Plants
Yong, J. N., & Ntie‐Kang, F. (2014) · Anti-Infective Agents · doi:10.2174/2211352512666140417002335 · Cited by 10
“1), a synthetic diarylquinoline which has a new mechanism of action against tuberculosis, is a promising drug that has been approved by the US FDA in half a century, for clinical trials [5-7].”
BackgroundLaHood, A., Rahman, R., McKenna, L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271102 · Cited by 10
Chaudhary, D., Singh, A., Marzuki, M., Ghosh, A., Kidwai, S., Gosain, T. P., Chawla, K., Gupta, S. K., Agarwal, N., Saha, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16468-w · Cited by 10
Gu, J., Wu, Q., Zhang, Q., You, Q., & Wang, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114742 · Cited by 11
Vanoxerine kills mycobacteria through membrane depolarization and efflux inhibition
Kingdon, A. D. H., John, A.-R. M., Batt, S. M., & Besra, G. S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1112491 · Cited by 9
“In contrast, vanoxerine did not alter the MIC99 of bedaquiline, which may be due to these drugs having analogous mechanisms, both disrupting the PMF and hence having a similar cellular effect (Andries et al., 2005; Feng et al., 2015).”
BackgroundRana, H. K., Singh, A. K., Kumar, R., & Pandey, A. K. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02679-z · Cited by 10
“Bedaquiline works by means of a novel mechanism consisting of the inhibition of the mycobacterial ATP synthase proton pump, an enzyme that is unique to Mtb and is necessary for them to transfer energy for reproduction (Andries et al. 2005).”
Unravelling the Secrets of Mycobacterial Cidality through the Lens of Antisense
Kaur, P., Datta, S., Shandil, R. K., Kumar, N., Nanduri, R., Sokhi, U. K., Guptha, S., Narayanan, S., Anbarasu, A., & Ramaiah, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154513 · Cited by 10
Campanerut-Sá, P. A., Ghiraldi‐Lopes, L. D., Meneguello, J. E., et al. (2016) · Future Microbiology · doi:10.2217/fmb-2016-5000 · Cited by 10
Synthesis, characterization and biological activity of fluorescently labeled bedaquiline analogues
Rombouts, J. A., Veenboer, R. M. P., Villellas, C., Lü, P., Ehlers, A. W., Andries, K., Koul, A., Lill, H., Ruijter, E., Orrù, R. V. A., et al. (2016) · RSC Advances · doi:10.1039/c6ra22693k · Cited by 11
Self-citationMachado, D., Azzali, E., Couto, I., Costantino, G., Pieroni, M., & Viveiros, M. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0110 · Cited by 10
Khan, S. R., Venugopal, U., Chandra, G., Bharti, S., Maurya, R. K., & Krishnan, M. Y. (2019) · Tuberculosis · doi:10.1016/j.tube.2019.02.007 · Cited by 10
Efficient circular gene knockout system for strain DSM 7029 and mc 155
Lei, X., Fan, Q., Huang, T. J., et al. (2019) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmz054 · Cited by 10
Respiratory Membrane Protein Complexes Convert Chemical Energy
Muras, V., Toulouse, C., Fritz, G., & Steuber, J. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-18768-2_10 · Cited by 11
Momin, M. A. M., Rangnekar, B., Larson, I. C., et al. (2019) · Advanced Powder Technology · doi:10.1016/j.apt.2019.07.016 · Cited by 10
Saw, W. G., Wong, C. F., Dick, T., & Grüber, G. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.098 · Cited by 10
Li, D., Liu, C., Jiang, X., Lin, Y., Zhang, J., Li, Y., You, X., Jiang, W., Chen, M., Xu, Y., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112898 · Cited by 10
Advances in host‐based screening for compounds with intracellular anti‐mycobacterial activity
Subhash, N., & Sundaramurthy, V. (2021) · Cellular Microbiology · doi:10.1111/cmi.13337 · Cited by 10
“Indeed, Bedaquiline and Delaminid, two new TB drugs, have new target pathways, namely, ATP synthesis and mycolic acid synthesis, respectively (Andries et al., 2005; Matsumoto et al., 2006).”
BackgroundBarbaro, L., Nagalingam, G., Triccas, J. A., Tan, L., West, N. P., Baell, J. B., & Priebbenow, D. L. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00063b · Cited by 11
Wu, H., Tian, Y., Wang, X., et al. (2021) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.15672 · Cited by 10
Sekiya, M. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00396 · Cited by 10
Anti-Leprosy Drugs: Modes of Action and Mechanisms of Resistance in Mycobacterium leprae
Cambau, E., & Williams, D. L. (2019) · doi:10.1489/itl.5.2 · Cited by 13
Self-citationMaeda, M. (2008) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-008-9135-0 · Cited by 10
“…arrows indicate the mutations conferring diarylquinoline (R207910) and mefloquine resistance for the c subunit of Mycobacterium tuberculosis and Mycobacterium smegmatis (Andries et al. 2005; Petrella et al. 2006), and Streptococcus pneumoniae ATP synthase (Martín-Galiano et al. 2002), respectively.”
BackgroundInfluentialThe eradication of leprosy: molecular modeling techniques for novel drug discovery
Anusuya, S., & Natarajan, J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.826188 · Cited by 10
“leprae and are found to play a crucial role in the survival of the pathogen [86-94].”
BackgroundSignificance of αThr-349 in the Catalytic Sites of Escherichia coli ATP Synthase
Ahmad, Z., Winjobi, M., & Kabir, M. A. (2014) · Biochemistry · doi:10.1021/bi5013063 · Cited by 10
Review of knowledge for rational design and identification of anti-tubercular compounds
Siddiqi, M. I., & Kumar, A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903253876 · Cited by 10
“Some of the recently discovered anti-tuberculosis agents other than those based on first- and second-line drugs include nitroimidazopyrans and nitroimidaoxazoles [39,40], oxazolidinones [41-43], clofazimine analogues [44,45], nitrofuranyl amides [46], purines [47-49], diarylquinolines [50,51], 1,2,4-benzothiadiazines…”
BackgroundZhao, C., Syed, H., Hassan, S. S., et al. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.01.009 · Cited by 10
In Vitro Antimycobacterial Activity of New 7-Chloroquinoline Derivatives
Bueno, J., Ruíz, F. A. R., Estupiñan, S. V., et al. (2012) · Letters in Drug Design & Discovery · doi:10.2174/157018012799079761 · Cited by 10
“Among these, the diarylquinoline TMC207 (ex R207910) [5] and the agent NAS91 [6] are very promising agents against MDR-TB (Fig.”
Background1.1 Introduction: The Importance of Chirality in Drugs and Agrochemicals
Cossy, J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-08-095167-6.00101-4 · Cited by 10
Wallace, R. J., Philley, J. V., & Griffith, D. E. (2015) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-1-4557-4801-3.00038-2 · Cited by 10
Acinetobacter baumannii OxPhos inhibitors as selective anti-infective agents
Rubin, H. N., Selwood, T., Yano, T., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.11.020 · Cited by 10
Effects of low incubation temperatures on the bactericidal activity of anti-tuberculosis drugs
Coleman, D., Waddell, S. J., & Mitchison, D. A. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq414 · Cited by 11
Tuberculosis Drug Discovery: Issues, Gaps and the Way Forward
Dartois, V. A., Leong, F. J., & Dick, T. (2009) · Wiley eBooks · doi:10.1002/9783527626816.ch21 · Cited by 10
Warrier, T., Romano, K. P., Clatworthy, A. E., & Hung, D. T. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.04.006 · Cited by 9
Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients
Shang, Y., Chen, S., Shi, W., et al. (2023) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2023.04.003 · Cited by 9
Mycobacterial FtsZ and inhibitors: a promising target for the anti-tubercular drug development
Shinde, Y., Pathan, A., Chinnam, S., Rathod, G. K., Patil, B. R., Dhangar, M. S., Mathew, B., Kim, H., Mundada, A. B., Kukreti, N., et al. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10759-8 · Cited by 9
The Mycobacterium tuberculosis MmpL3 inhibitor MSU-43085 is active in a mouse model of infection
Williams, J. T., Giletto, M. B., Haiderer, E. R., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03677-23 · Cited by 9
Gao, F., Li, J., Zhang, G., et al. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00415 · Cited by 9
Roberts, L. W., Malone, K. M., Hunt, M., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00053-3 · Cited by 9
Intermolecular Regioselective Alkylarylation of Vinylarenes via Photoredox/Nickel Dual Catalysis
Pan, X.-H., Hou, Y.-P., Shi, C.-X., et al. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c02205 · Cited by 9
Ragunathan, P., Sae‐Lao, P., Harikishore, A., Daher, W., Roquet, F., Kremer, L., Bates, R. W., & Grüber, G. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae406 · Cited by 10
Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis
Xiong, X., Xu, Z., Yang, Z., Liu, Y., Wang, D., Dong, M., Parker, E. J., & Zhu, W. (2013) · Current Drug Targets · doi:10.2174/1389450111314060009 · Cited by 11
Brown, A. K., Aljohani, A. K. B., Alsalem, F. M. A., Broadhead, J. L., Gill, J. H., Lu, Y., & Sellars, J. D. (2020) · Molecules · doi:10.3390/molecules25102387 · Cited by 11
“The diarylquinoline Bedaquiline (SIRTURO®®), used predominantly against drug-resistant TB, targets the mycobacterial respiratory chain enzyme F1/F0-ATPase [11,12].”
BackgroundEarly Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era
Minias, A. E., Żukowska, L., Lechowicz, E., Gąsior, F., Knast, A., Podlewska, S., Zygała-Pytlos, D., & Dziadek, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.618168 · Cited by 9
Singh, P., Rawat, S., Agrahari, A. K., Singh, M., Chugh, S., Gurcha, S. S., Singh, A., Abrahams, K. A., Besra, G. S., Asthana, S., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02592-22 · Cited by 9
Treatment options for children with multi-drug resistant tuberculosis
Bossù, G., Autore, G., Bernardi, L., Buonsenso, D., Migliori, G. B., & Esposito, S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2148653 · Cited by 10
Molecular mechanism for the involvement of CYP2E1/NF-κB axis in bedaquiline-induced hepatotoxicity
Kotwal, P., Khajuria, P., Dhiman, S., Kour, D., Dhiman, S. K., Kumar, A., & Nandi, U. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121375 · Cited by 9
Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli
Sau, S., Roy, A., Agnivesh, P. K., Kumar, S., Guru, S. K., Sharma, S., & Kalia, N. P. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001695 · Cited by 9
Robey, J. M. S., Maity, S., Aleshire, S. L., Ghosh, A., Yadaw, A., Roy, S., Mear, S. J., Jamison, T. F., Sirasani, G., Senanayake, C. H., et al. (2023) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00287 · Cited by 9
Metadata
- Authors
- Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N., & Jarlier, V.
- Affiliations
- Johnson & Johnson (United Kingdom) (GB)
- Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
- Corresponding author
- Andries, Koen
- Lounis, Nacer
- Venue
- Science
- Published
- 2005-01-14
- Volume
- 307
- Issue
- 5707
- Pages
- 223-227
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2158658436
- Cited by
- 2,191
- References
- 13
- Citations by year
- 2026: 63 · 2025: 98 · 2024: 103 · 2023: 106 · 2022: 111 · 2021: 98 · 2020: 136 · 2019: 141 · 2018: 102 · 2017: 124 · 2016: 120 · 2015: 129 · 2014: 140 · 2013: 106 · 2012: 102
- FWCI
- 27.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- diarylquinolines, Mycobacterium tuberculosis, tuberculosis drug resistance, ATP synthase inhibition, proton pump, bactericidal activity, combination therapy, isoniazid
- MeSH terms
- Amino Acid Sequence, Animals, Antitubercular Agents, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drug Therapy, Combination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
